News Hub | News Direct

Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
Article thumbnail News Release

Taglich Brothers Maintains Speculative Buy Rating On Cosmos Health With $4 Price Target, Highlighting Potential Valuation Upside

Marel Corporation Ltd

By Marel Corp Cosmos Health ($COSM or 'Cosmos') is a global healthcare group that remains significantly undervalued by the market, despite strong execution and broad diversification across multiple sectors. The company boasts an innovative R&D division that leverages AI-driven drug repurposing, along with ownership of proprietary pharmaceutical and nutraceutical brands like Sky Premium Life. As a vertically integrated manufacturer of medicines, Cosmos is strategically positioned within the healthcare industry. Additionally, its logistics arm, CosmoFarm, distributes healthcare products to over 1,000 pharmacies, while its telehealth platform further strengthens the company’s presence in the evolving healthcare landscape. Despite the company generating nearly $60 million in annual revenue—expected to grow to $155.80 million by 2027, according to the company’s guidance for the 2024-2027 period—its market cap remains depressed at just around $20 million. The share price has dropped significantly over the past couple of years, despite notable progress on multiple fronts. Based on the guidance provided issued by the company, it expects to be highly profitable in the coming years, with EBITDA projected to reach nearly $30 million by 2027. Specifically, the company issued the following guidance: The anticipated achievements are expected to result from a combination of strategic initiatives, including a focus on higher-margin business segments, operational synergies, and enhanced cost efficiency. As highlighted by the company, the following key priorities could drive this growth: Expansion of Sky Premium Life's global footprint and product range, introducing new formulas, therapeutic areas, and customized offerings. This will be supported by strategic partnerships with exclusive distributors and digital channels. Global launch of C-Sept and C-Scrub, both of which possess significant market potential and face limited competition. Production is being scaled up, with additional products in the development pipeline. Expansion of generic pharmaceuticals across the EU and international markets, with a focus on advanced generics and innovative OTC products. Optimization of Contract Manufacturing Organization (CMO) operations, prioritizing high-demand medicines and competitive pricing strategies. Progress toward World Medical Organization (WMO) patent approval and completion of clinical trials for the CCX obesity pill by 2025, with commercialization anticipated in 2026. Driving organic growth by integrating the pharmacy distribution network to enhance efficiency and scalability. Corporate reorganization efforts, focusing on cost-cutting initiatives and optimizing asset and resource utilization through the integration of business units. These initiatives aim to propel the company forward while delivering sustained profitability and operational growth. Sharing the company’s optimistic outlook, Taglich Brothers recently published an updated research report on the company's common stock. Taglich maintains a Speculative Buy rating with a $4 price target, implying a nearly four-fold increase in the share price over the next 12 months. Taglich estimates that the company’s valuation should improve alongside revenue growth, which is expected to translate into operating profits and positive cash flow. Currently, Cosmos's price-to-sales multiple (0.3x) significantly trails the sector average of 2.4x for comparable companies in medical distribution and drug manufacturing, indicating a potential catch-up opportunity. Moving forward, investors are likely to assign a valuation multiple closer to industry norms. Even with a conservative approach, applying a lower-than-average price-to-sales multiple of 1.4x to the 2025 sales per share forecast of $3.86 supports the $4 price target, accounting for execution risks and potential warrant dilution. Recently, the company has rapidly secured distribution agreements for its proprietary Sky Premium Life brand across the GCC—including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates—as well as in European markets like Slovakia, Hungary, Poland, and Czechia. It has even signed exclusivity agreements to distribute real-time mpox (formerly monkeypox) PCR tests as far as India. In summary, Cosmos Health is a company worth monitoring as it works to position itself for potential alignment with industry peers. Featured image sourced from Shutterstock Marel Corp is an investor in stocks, employing diverse strategies across sectors and company sizes. This post was authored by an external contributor and does not represent Benzinga's opinions and has not been edited for content. This contains sponsored content and is for informational purposes only and not intended to be investing advice. Contact Details BDG Communications +44 20 7097 1653 info@bdgcommunications.com

September 24, 2024 12:00 PM Eastern Daylight Time

Image
Article thumbnail News Release

AI Unpacks Generational Stereotypes, Highlighting Key Differences, but Beer Bridges the Gap

AIport

What happens when you ask generative AI models to depict Baby Boomers, Gen X, Millennials, and Gen Z? You might expect tech-challenged Boomers and avocado-loving Millennials. But what you get is far more interesting and in some cases, unexpected. A joint research project conducted by AIport and Turing Post last month analyzed over 1200 AI-generated images across four different models—Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG. The findings have revealed both familiar stereotypes and surprising quirks about how AI perceives these generations. Sad Boomers, Happy Zoomers? Contrary to the carefree Boomer stereotype, AI models like Midjourney depict Baby Boomers as introspective, or even somber, often bundled up and gazing wistfully into the distance—a reflection, perhaps, of their disillusionment with the unfulfilled ideals of the 1960s cultural revolution. However, the ERNIE-ViLG model, likely trained on datasets with a more collectivist cultural slant, shows 93% of Boomers smiling. This fascinating contrast underscores the cultural differences embedded in different AI models. Meanwhile, Gen Z’s images are vibrant and diverse, reflecting their reputation as a generation that embraces individuality, inclusivity, and self-expression. The AI-generated images depict Zoomers in colorful, highly detailed scenarios, making them the most visually distinct generation in the study. Generations Through the AI Lens The research explored how generations are portrayed in five key aspects of life: identity, relationships, work, lifestyle, and consumer habits. The AI models revealed consistent patterns and stereotypes; for example, males predominated in the depictions of Boomers and Gen Xers across all four models, while many images of Millennials and Zoomers showed greater diversity and more female representation. Surprisingly, Gen X appears to be the least well-understood generation by AI, characterized by fewer defining features compared to all other generations, likely due to the limited amount of training data available. The one stereotypical Gen X leitmotif that AI consistently identifies is their fondness for flannel shirts—an unmistakable symbol of the 1990s grunge scene worn by Gen Xers who were rebellious teenagers and young adults during that era. As for one (un)expected commonality… It’s beer. Whether they’re Millennials job-hopping or Boomers reminiscing about the good old days, AI consistently showed beer in 34% of the produced images across all generations. Prompt Engineering and AI Insights The prompts for this research were carefully crafted to avoid bias, using neutral phrases like "A Millennial at work" or "A Boomer relaxing." The results offer a telling look at how generative AI models mirror societal stereotypes, often shaped by the data they're trained on. These findings open the door to deeper discussions on how AI reflects, and sometimes distorts, cultural narratives. "Whether we think we can learn about generations from these images depends upon how confident we feel that the training data that went in is an accurate image of the self identity of a group,” explains Senior Engineer and Sociologist Stephanie Kirmer, who analyzed the findings. “For the younger sets, I don’t think we can know how much of it is media representation created by people outside the group versus how much is selfie-style personal expression. Some of what we’re getting, especially for the older groups who don’t contribute as much self-generated visual media online, is perceptions of that group from advertising and media, which we know has inherent flaws." About the Study The study examined the outputs of four globally recognized generative AI models, each with distinct aesthetic and cultural nuances, providing a comprehensive look at how each generation is portrayed visually. The selected models included Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG, offering diverse perspectives from different regions across the globe. Conclusion Whether confirming or contradicting societal stereotypes, AI-generated images provide a fascinating snapshot of how technology interprets generational differences. The fact that beer remains a unifying theme across all four models shows that, no matter our age, some things—like enjoying a cold one—transcend generational divides. To learn more about the project, visit https://www.aigenerations.tech/. Hero images for the media: Google Drive Link About AIport AIport is an emerging community of AI/ML enthusiasts and practitioners with a goal of providing a truly global view of the AI/ML/DS landscape. https://www.blog.aiport.tech/ About Turing Post Turing Post is everything you need to make smarter decisions about AI. https://www.turingpost.com/ Contact Details Nick Leighton nick.leighton@nettresultsllc.com Company Website https://www.aigenerations.tech/

September 23, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

BestGrowthStocks.Com Issues Comprehensive Analysis of Globalstar Inc’s Strategic Partnerships and Growth Drivers

Global Star Inc. (GSAT)

NEW YORK, NY / NewsDirect / September 23rd, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Globalstar Inc. a satellite and terrestrial connectivity services as an international telecom infrastructure provider. Globalstar Inc. (NYSE: GSAT) has garnered significant investor attention following recently reported revenue growth. Best Growth Stock's full report analyzes Globalstar’s operations, competitive advantages and disadvantages, potential catalysts, growth drivers, strategic partnerships, financials, key customers, management evaluation, share structure, chart, support and resistance levels, and more. Access this full analysis free here: https://bestgrowthstocks.com/access-gsat-analysis/ About Globalstar Globalstar empowers its customers to connect, transmit, and communicate in smarter ways – easily, quickly, securely, and affordably – offering reliable satellite and terrestrial connectivity services as an international telecom infrastructure provider. The Company’s LEO satellite constellation assures secure data transmission for connecting and protecting assets, transmitting critical operational data, and saving lives for consumers, businesses, and government agencies across the globe. Globalstar’s terrestrial spectrum, Band 53, and its 5G variant, n53, offer carriers, cable companies, and system integrators a versatile, fully licensed channel for private networks with a growing ecosystem to improve customer wireless connectivity, while Globalstar’s XCOM RAN product offers significant capacity gains in dense wireless deployments. In addition to SPOT GPS messengers, Globalstar offers next-generation IoT hardware and software products for efficiently tracking and monitoring assets, processing smart data at the edge, and managing analytics with cloud-based telematics solutions to drive safety, productivity, and profitability. For more information, visit www.globalstar.com. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.Com SOURCE: BestGrowthStocks.Com Contact Details Media Source LLC Steve Macalbry +1 989-274-7778 editor@bestgrowthstocks.com Company Website https://bestgrowthstocks.com/

September 23, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Article thumbnail News Release

Join Benchmark International's Exclusive Webinar "Seller Motivation: What Goes Into the Decision to Sell?"

Benchmark International

Are you considering selling your business? Deciding when and why to sell is one of the most significant decisions you’ll ever make as a business owner. While maximizing financial proceeds is often at the forefront of these decisions, it’s essential to recognize that it’s not the only factor. Life circumstances, time with family, and other qualitative considerations can often outweigh financial gain. To help you navigate this complex process, we invite you to join our upcoming webinar: Seller Motivation: What Goes Into The Decision To Sell? Space is filling up fast, so register today! Why You Should Register Selling a business is about more than just crunching the numbers. In this exclusive webinar, you’ll gain valuable insights into the full spectrum of motivations that drive business owners to sell. Understanding these motivations can help you make a well-rounded and informed decision about your business’s future. This webinar is a must-attend for business owners contemplating the sale of their business, particularly in today’s strong but disciplined market. By attending, you’ll be better equipped to evaluate both the financial and personal factors that play a crucial role in this life-changing decision. Whether you’re focused on securing a comfortable financial future or prioritizing time with loved ones, the information presented will help you weigh these considerations effectively. Spots are limited, so don’t miss this opportunity to secure your spot. What You’ll Learn This webinar offers actionable insights into the decision-making process for business owners. Here’s what you can expect to learn: The wide range of reasons why business owners choose to sell, beyond just financial incentives How personal life events, such as family needs and future aspirations, can influence your decision A look at the current M&A market and how buyers are approaching valuations How to balance personal and financial goals using the concept of indifference curves, which help weigh non-monetary values like time with family against financial returns By attending, you’ll gain the tools to make a decision that aligns with your long-term vision—both personally and financially. Spots Are Filling Fast – Register Now! If you’re ready to gain clarity on your motivations for selling and align your decision with both your personal and financial goals, this is the webinar for you. Don’t miss out—register now and take the first step toward making a well-informed, strategic decision about the future of your business. ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

September 16, 2024 09:54 AM Eastern Daylight Time

Image
Article thumbnail News Release

Comcast to Expand Fiber Broadband Services Across Northern California

Comcast California

Comcast announced it will expand its reliable, smart, high-speed, fiber broadband network in both residential and commercial neighborhoods in Northern California’s Marin and Sutter counties. By mid-2026 these expansion efforts will bring Comcast’s next-generation network to over 150 locations in Marin County and over 450 locations in Sutter County, both of which had previously been unserved. This broadband network expansion is made possible by a $14 million Federal Funding Account (FFA) Grant from the California Public Utilities Commission (CPUC) and private funding by Comcast. Comcast also recently announced it has received a $26 million FFA grant to expand its fiber-rich network in Tulare County, which will bring broadband services to nearly 6,200 unserved locations by early 2026. “At Comcast we understand that reliable, high-speed Internet has become a necessity to not only support those looking to participate in the ever-growing digital economy, but also to connect students, families and seniors to those moments that matter the most,” said David Tashjian, Regional Senior Vice President of Comcast California. “This continued investment of funds from the California Public Utilities Commission (CPUC) will allow us to expand into unserved communities throughout Marin and Sutter Counties, which will provide residents and businesses with a future of unlimited possibilities.” “This grant project will help level the playing field for a lot of families in Sutter County who have not previously had access to high-speed Internet,” said Mat Conant, Chair of the Sutter County Board of Supervisors. “This is really important for anyone doing any research for school or work, and for small business owners.” “There has always been an overwhelming demand to improve and expand our broadband services in Marin County,” said Eric Lucan of the Marin County Board of Supervisors. “That need is particularly important for our senior community, including my constituents within a mobile home community in Novato. I commend the California Public Utilities Commission (CPUC) and Comcast on today’s announcement and I’m excited to see the lasting impacts these awards will have in connecting more residents to high-speed Internet and the economic opportunities they will create.” Comcast’s commitment to new communities goes beyond network expansion efforts, addressing digital opportunities in communities through Project UP, the company’s $1 billion dollar commitment to help tens of millions of people connect to the Internet and build futures of unlimited possibilities. Over the past three years, Comcast has invested more than $130 million in cash and in-kind donations into California nonprofits focused on helping people build digital skills, expanding WiFi connected Lift Zones and funding connectivity and Internet adoption programs. Comcast’s funding also supports ongoing efforts to build awareness about affordable connectivity services like Internet Essentials, which offers eligible households high-speed Internet for $9.95/month or Internet Essentials Plus for $29.95/month. Affordable computers are also available through Internet Essentials. Since its inception in 2011, the program has connected more than 2.2 million Californians. Residential customers will be able to take advantage of Xfinity’s full suite of products, including Internet, video, mobile, voice and managed home solutions. For local businesses, Comcast Business will offer a suite of connectivity, communications, networking, cybersecurity, wireless, and managed solutions to help organizations of different sizes prepare for what’s next. Industry analysts and associations have consistently recognized Comcast Business as a leader and innovator, and one of the fastest-growing providers of Ethernet services. Comcast’s network and Internet experience are powering homes today and into the future. Ultimate Capacity: Xfinity customers connect more than 1 billion devices across the company’s network annually. With the next-generation Xfinity gateways, we deliver the most advanced WiFi technology carrying three times more bandwidth to power streaming, gaming, videoconferencing, and more, simultaneously. Fastest Internet: Nearly a third of Xfinity Internet customers subscribe to gigabit speed products. Recently Comcast connected the first customers in the world to a DOCSIS 4.0 connection, delivering symmetrical gig speeds over existing connections in customers’ homes with plans to continue to rollout these speeds across the country over the coming years. Unprecedented Coverage: The latest Xfinity Gateway provides a more reliable connection throughout the home. Customers can get wall-to-wall WiFi coverage with a powerful WiFi Boost Pod that extends coverage to hard-to-reach areas of the home. Most Reliable Connection: Comcast is scaling the nation’s largest and most reliable network that passes 62 million homes and businesses and counting. The company launched Storm-Ready WiFi, a new device that comes powered with cellular and battery backup to help keep customers connected even when the power goes out. Ultra-Low Latency: The Xfinity network and the latest Xfinity Gateway are a powerful combination that deliver ultra-low latency for those moments when response times matter most like video games, a fast-growing category with Xfinity households averaging more than one gaming console per home. For local businesses, Comcast Business will offer a suite of connectivity, communications, networking, cybersecurity, wireless, and managed solutions to help organizations of different sizes prepare for what’s next. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest-growing providers of Ethernet services. ### About Comcast Business Comcast Business offers leading global businesses the technology solutions and forward-thinking partnership they need. With a full suite of solutions including fast, reliable connectivity, secure networking solutions and advanced cybersecurity and a range of managed service options, Comcast Business is ready to meet the needs of businesses of all sizes. Comcast Business has been recognized by leading analyst firms for its continued growth, innovation, and leadership, and is committed to partnering with customers to help them drive their businesses forward. For more information, call 800-501-6000. Follow @ComcastBusiness on social media networks at http://business.comcast.com/social. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Comcast California Jon Koriel +1 925-315-2690 jon_koriel@comcast.com Company Website https://california.comcast.com/

September 12, 2024 01:46 PM Pacific Daylight Time

Article thumbnail News Release

Kevel and Placements.io Announce Strategic Partnership to Address Unique Challenges in Retail Media

Kevel

Kevel, the API-first ad serving company for building custom, in-house ad platforms, and Placements.io, the leading revenue management platform for media companies, today announced a strategic partnership that will empower retailers and ecommerce brands to seamlessly manage, optimize and scale their retail media networks with unparalleled flexibility and precision. The partnership will integrate Kevel’s state-of-the-art Retail Media Cloud™ solution with Placements.io revenue management system. With this unified platform, retailers can manage, monetize and scale their ad inventory effectively in-house, which will help to maximize return on ad spend and drive more significant results from retail media investments. “At Kevel, we’re committed to providing our clients with the tools they need to succeed and scale their retail media networks,” commented James Avery, CEO of Kevel. “This partnership is a no-brainer for us - we are aligned with Placements.io in our relentless drive to make the internet a better place. Now, we can extend our capabilities even further to offer a more comprehensive solution that meets the complex needs of our retail and ecommerce customers.” As retail media continues to grow at an unprecedented rate, the ability to efficiently manage ad inventory, optimize campaigns, and maximize revenue while maintaining control of data and reporting has become crucial for retailers. “This partnership can help unlock revenue opportunities for retailers, ecommerce and media companies,” said Edwin Fu, Founder and CEO of Placements.io. “By bringing together two powerful platforms, retailers can achieve their goals with greater accuracy and efficiency.” By integrating Kevel’s cutting-edge API infrastructure with Placements.io’s robust order and billing management capabilities, this partnership aims to provide a solution that unifies processes and data across ad operations, sales, and finance to show the true value of advertising and address the unique challenges of the retail media landscape. Key Benefits of the Partnership: Enhanced Customization: Retailers can now build fully-customized ad platforms, streamline operations, and take advantage of advanced revenue management tools. Seamless Integration: Combining Kevel and Placements.io’s tech on one unified platform will help retailers manage and monetize their ad inventory more effectively. Scalable Solutions: Both platforms are built to scale, allowing retailers to expand their retail media networks without the limitation of traditional black-box ad tech solutions. Improved ROI: The collaboration will help retailers and ecommerce brands maximize return on ad spend, driving more significant results from their retail media investments. This partnership underscores both companies’ commitment to raising the bar within ad tech and retail media. By joining forces, Kevel and Placements.io are at the forefront of empowering today’s modern retailers to build custom, in-house, privacy-first, revenue-generating ad platforms that can adapt to the rapidly changing digital advertising landscape. For more information about the partnership and how it can benefit your business, please visit Kevel.com and Placements.io. About Kevel Kevel is powering innovative, flexible ad tech infrastructure APIs that fuel its Retail Media Cloud™. This unique offering is the only API-based solution for in-housing retail media technology that enables multi-brand retailers to differentiate based on their unique brand, improving shopper experience while maintaining total control of their first-party data.Kevel believes that every digital retailer should have the capability to build and scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Delivery Hero, Sonae, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media networks with Kevel. The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com About Placements.io Placements.io was founded in 2014 to provide a more modern platform for companies buying and selling digital-focused, omnichannel advertising. Placements.io powers over $12B in annual ad revenue for publishers, broadcasters, OTT/CTV companies, retailers, and emerging media companies. Placements.io has offices across the U.S. and in London, Singapore, and Taiwan. Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 jchoo@kevel.com Placements.io Lindsey Bradshaw lindseyb@placements.io

September 11, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Alvarez & Marsal Report: Top Private Brand Retailers Outperform the Market: 7 out of Top 10 Retailers by Grocery Dollar Share Are Top Private Brand Players

Alvarez & Marsal Consumer and Retail Group

· U.S. Private Label spending is 20% of total market, projected to rise to 24% by 2030 · Top 4 Private Brand retailers had 144% stock price growth in past 5 years · Over 250 new stores have been opened by top Private Brand retailers in the past year Global professional services firm Alvarez & Marsal’s Consumer and Retail Group (A&M CRG) has released its latest report, Accelerate your Private Brand journey to win with customers and shareholders, which looks at how the Private Label market is accelerating even amid slower total grocery market growth, and what retailers need to do to gain and maintain success with their private brands. The report lays out the case for private label traction as a strategic imperative for grocers and provides examples of the ways in which prominent Private Brand retailers have built stronger loyalty and advocacy with their customers while delivering superior returns for their shareholders. “There’s a strong correlation between the most successful private brand grocers and their market share and financial performance,” noted Marco Valentini, Managing Director at Alvarez & Marsal’s Consumer and Retail Group. “The best players act differently from the rest of the pack. Their C-level executives are committed to growing their own brands and driving differentiation through them. Chief Merchants treat their Private Brands with the same priority and attention as they do National Brands. Marketing and branding efforts are aimed at elevating and differentiating products and increasing overall customer awareness and advocacy of their brands. Finally, product innovation cycles need to reflect the yearly cadence of line reviews and retailers must be able to constantly innovate and update their ‘Own Brand’ products.” The report lays out key enablers to winning with private brands, and the benefits of having a Private Brand strategy, including: · Value perception: Private Brand products should be 30 to 50% less expensive than National Brands and provide same or better quality. The majority of consumers cite value as a key driver of purchase. · Product innovation/differentiation: Private Brand products can be tailored to align with customer demographics and preferences. The second most important attribute that drives purchase of private brands is quality/taste. · Margin management: Private Brand margins typically surpass those of National Brands and the individual product should provide the same or better unit economics (“penny profit”) than their National Brand equivalents. Private Brands are a very effective way to drive value for customers in addition to price and promotion investment, which often dilute margins. · Brand development: More than 8 in 10 shoppers make decisions based on brand trust, so developing private label brands that resonate with consumers and provide strong advocacy is critical. Successful Private Brands can drive positive impact to retailers’ overall banner brand perception. · Sustainable sourcing: Direct control over product development, packaging, sourcing and supply chain can support specific sustainability goals. This is an important factor, especially for Gen Z and Millennial shoppers. "For many grocery retailers today, the lack of a comprehensive Private Brand strategy means that they’ll get left behind,” said John Clear, Senior Director in Alvarez & Marsal’s Consumer and Retail Group. “To unlock the value of private label, grocers need to have a clear plan in place: a differentiated brand architecture and consistent positioning across categories; scalable processes and innovation capabilities that will ensure their success is repeatable.” To download a pdf of Accelerate your Private Brand journey to win with customers and shareholders, please visit: https://alvarezandmarsal-crg.com/insight/accelerate-your-private-brand-journey-to-win-with-customers-and-shareholders/ The Alvarez and Marsal Consumer and Retail Group (CRG) is a management consulting firm that tackles the most complex challenges and advances its clients, people, and communities toward their maximum potential. CRG combines the best of A&M’s broader firm bias toward action and practicality with deep consumer and retail industry experience. CRG partners with businesses across a wide range of categories including Grocery, Mass, Convenience, Discount/Dollar, Wholesale/Distribution, Food & Beverage, Beauty & Personal Care, and Apparel & Footwear to drive significant performance improvement. Contact Details David Schneidman dschneidman@alvarezandmarsal.com Company Website https://www.alvarezandmarsal.com/industries/retail/retail

September 10, 2024 02:00 PM Eastern Daylight Time

Article thumbnail News Release

VOESH New York Launches New 28 oz. Vegan Hand & Body Crème Collection

VOESH New York

VOESH New York is debuting a new 28 oz. Vegan Hand & Body Crème Collection, created to provide salon clients with a luxurious and healthier hydration experience. These larger bottles offer the same high-quality, vegan-friendly ingredients that have established VOESH as a leader in the body care industry. “We’re thrilled about the addition of these generously sized lotions to VOESH’s product line,” said Tom Harrison, Principal of Coleman Harrison. “VOESH consistently outshines the competition with expert formulas. This new size will undoubtedly enhance manicure and pedicure services, delivering superior results for both clients and technicians.” “As a bonus, technicians can pair these lotions with VOESH’s best-selling Pedi in a Box products,” added Kendall Stone, Principal of Jay Stone Sales. Enriched with 94+% natural-origin ingredients, VOESH’s 28 oz. crèmes are formulated with organic virgin olive oil and natural extracts. They are infused with 100% vegan, clean, and certified organic components and are free from parabens, phthalates, gluten, mineral oil, and more than 1,680 other potentially harmful substances. The velvety texture provides long-lasting moisture and a radiant glow without a greasy feel. These larger bottles not only provide a superior experience but also ensure lasting hydration and value. “Our lotions have always been a best-seller, so we’ve brought them back in a more convenient size for salons,” said Joseph Choi, Co-Founder of VOESH New York. “Salon owners have been asking for our popular massage butter in a bottle, and we’re ecstatic to fulfill this request.” The new collection is available in five delightful scents: Olive Sensation, Lavender Relieve, Vitamin Recharge, Jasmine Soothe, and Green Tea Detox. Each scent is made with premium, IFRA-certified fragrances that pair perfectly with VOESH’s best-selling Pedi in a Box Deluxe 4 Step pedicure kits. This allows for a cohesive pampering experience that caters to clients’ preferences. With a transparent ingredient list, dermatologist testing, and U.S. FDA registration, VOESH’s new 28 oz. Vegan Hand & Body Crèmes are the best addition to guarantee clients and technicians feel good about what goes on their skin. For more information about VOESH’s new 28 oz. Vegan Hand & Body Crèmes, please visit voeshpro.com. About VOESH New York: Founded in 2013, VOESH New York has emerged as a premier destination for clean and efficacious body care solutions catering to head-to-toe wellness. Noteworthy products include Pedi in a Box, Mani in a Box, the award-winning Shower & Empower Vitamin C Shower Filter, and Collagen Gloves and Socks. VOESH New York is committed to providing 100% vegan, cruelty-free, and sustainable products because every body deserves better beauty! All VOESH New York products are certified by PETA and registered with the US Mocra, EU CPNP and UK SCPN, maintaining vegan, cruelty-free, and dermatologist-tested standards. VOESH New York proudly excludes all 1,680+ EU-banned ingredients and an additional 400+ potentially harmful ingredients. For more information, visit VOESH New York’s website at Voesh.com or contact press@voesh.com. All VOESH New York products are certified by PETA and registered with the EU CPNP, and UK SCPN. Always vegan, cruelty-free, and dermatologist-tested, VOESH New York proudly excludes all 1,680+ EU-banned ingredients and an additional 400+ potentially harmful ingredients. Contact Details Colleen Mathis +1 917-690-5560 Colleen@absoluterrelations.com Company Website https://voesh.com/

September 06, 2024 08:00 AM Eastern Daylight Time

12345 ... 166